Studying Genes for Barrett's Esophagus in Brothers and Sisters

Sponsor
Medical Research Council (Other)
Overall Status
Unknown status
CT.gov ID
NCT00516347
Collaborator
(none)
400
1

Study Details

Study Description

Brief Summary

RATIONALE: Learning about how often heartburn and other risk factors occur in brothers and sisters and other family members of patients with Barrett's esophagus may help identify other individuals at risk and identify genes for Barrett's esophagus.

PURPOSE: This clinical trial is studying genes for Barrett's esophagus in brothers and sisters.

Condition or Disease Intervention/Treatment Phase
  • Genetic: comparative genomic hybridization
  • Genetic: genetic linkage analysis
  • Other: laboratory biomarker analysis
  • Other: questionnaire administration
  • Procedure: study of high risk factors

Detailed Description

OBJECTIVES:

Primary

  • To investigate the familial incidence of heartburn and Barrett's esophagus in first and second degree relatives of patients with Barrett's esophagus in the United Kingdom.

  • To determine susceptibility genes for Barrett's esophagus in affected sibling pairs.

  • To examine gene-environment interactions, such as smoking, alcohol, and Helicobacter pylori status, on familial susceptibility to heartburn and Barrett's esophagus.

Secondary

  • To compare the mortality from esophageal adenocarcinoma in family members with heartburn and Barrett's esophagus with deaths from other causes.

OUTLINE: This is a multicenter study.

Patients complete a family history questionnaire. Epidemiological data is also collected about environmental exposures, such as smoking and alcohol history. Any siblings or other living family members affected by heartburn identified from this survey are then contacted to validate their symptoms/diagnoses and to collect other relevant epidemiological data. Family members with heartburn are offered a screening endoscopy for the presence of Barrett's esophagus. In the absence of an endoscopy, a symptom nomogram predictive for the presence of Barrett's esophagus is used.

Patients and their siblings, as well as any other willing family member (affected or non-affected) are asked to have a blood sample (EDTA tube for genetic analysis and a serum sample for Helicobacter pylori status) taken by their physician. Genomic DNA is extracted from lymphocytes and a genome-wide scan is performed using a standard marker set. A computer program is used to verify sibling relationships. Individuals not found to be full siblings are excluded from subsequent analyses. Maximum likelihood score (MLS) and the nonparametric linkage score (NPL) is used to estimate the degree of linkage.

All study participants are flagged with the National Health Service (NHS) Central Register to ascertain the future mortality from esophageal adenocarcinoma compared with deaths from other causes.

PROJECTED ACCRUAL: A total of 200 sibling pairs will be accrued for this study.

Study Design

Study Type:
Observational
Anticipated Enrollment :
400 participants
Official Title:
A Sibling Pair Study To Identify Barrett's Oesophagus Susceptibility Genes
Study Start Date :
Jun 1, 2002

Outcome Measures

Primary Outcome Measures

  1. Familial incidence of heartburn and Barrett's esophagus in first and second degree relatives of patients with Barrett's esophagus []

  2. Susceptibility genes for Barrett's esophagus in affected sibling pairs []

  3. Gene-environment interactions, such as smoking, alcohol, and Helicobacter pylori status, on familial susceptibility to heartburn and Barrett's esophagus []

Secondary Outcome Measures

  1. Comparison of the mortality from esophageal adenocarcinoma in family members with heartburn and Barrett's esophagus with deaths from other causes []

Eligibility Criteria

Criteria

Ages Eligible for Study:
N/A and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
DISEASE CHARACTERISTICS:
  • Sibling pairs will be recruited either from the United Kingdom National Barrett's Oesophagus Registry (UKBOR) of patients with Barrett's esophagus from 37 centers OR from National Health Service hospitals
PATIENT CHARACTERISTICS:
  • Not specified
PRIOR CONCURRENT THERAPY:
  • Not specified

Contacts and Locations

Locations

Site City State Country Postal Code
1 Hutchison Cancer Research Unit Cambridge England United Kingdom CB2 2XZ

Sponsors and Collaborators

  • Medical Research Council

Investigators

  • Study Chair: Rebecca Fitzgerald, MD, Hutchison Cancer Research Unit

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
, ,
ClinicalTrials.gov Identifier:
NCT00516347
Other Study ID Numbers:
  • MRC-HCRC-MREC-02/2/57
  • CDR0000561079
  • EU-20752
First Posted:
Aug 15, 2007
Last Update Posted:
Aug 12, 2013
Last Verified:
Oct 1, 2007

Study Results

No Results Posted as of Aug 12, 2013